Risk factors and medical follow-up of drug users tested for hepatitis C - can the risk of transmission be reduced?

被引:23
作者
Serfaty, MA
Lawrie, A
Smith, B
Brind, AM
Watson, JP
Gilvarry, E
Bassendine, MF
机构
[1] Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Specialist Drug & Alcohol Unit, Newcastle Upon Tyne NE1 6UR, Tyne & Wear, England
关键词
hepatitis C; intravenous drug users; risk factors; medical follow-up; methadone maintenance;
D O I
10.1080/09595239700186721
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Of 1728 patients attending a regional drug and alcohol clinic, 202 were considered at risk of hepatitis C virus (HCV). Forty-nine per cent (99/202) agreed to testing-67% (67) were HCV antibody positive. Age and a history of needle sharing was the significant factor associated with positive HCV status. Patients on methadone maintenance medication were more-likely to have been HCV positive, but significantly (p = 0.005) less likely to have shared needles in the previous year. Seventy-three per cent (49/67) attended for follow-up at a "liver clinic". Fifty per cent were infected with genotype la. Eighteen patients were biopsied and all were abnormal, ranging from mild hepatitis to severe fibrotic hepatitis. Attendance for medical follow-up was poor, which emphasizes the importance of preventative measures such as methadone maintenance programmes for reducing the spread of HCV.
引用
收藏
页码:339 / 347
页数:9
相关论文
共 25 条
[1]   HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV [J].
ALBERTI, A ;
MORSICA, G ;
CHEMELLO, L ;
CAVALLETTO, D ;
NOVENTA, F ;
PONTISSO, P ;
RUOL, A .
LANCET, 1992, 340 (8821) :697-698
[2]   THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES [J].
ALTER, MJ ;
MARGOLIS, HS ;
KRAWCZYNSKI, K ;
JUDSON, FN ;
MARES, A ;
ALEXANDER, WJ ;
HU, PY ;
MILLER, JK ;
GERBER, MA ;
SAMPLINER, RE ;
MEEKS, EL ;
BEACH, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (27) :1899-1905
[3]  
Armitage P., 2001, STAT METHODS MED RES, V4th
[4]   HEPATITIS-C VIRUS IN INTRAVENOUS-DRUG-USERS [J].
BELL, J ;
BATEY, RG ;
FARRELL, GC ;
CREWE, EB ;
CUNNINGHAM, AL ;
BYTH, K .
MEDICAL JOURNAL OF AUSTRALIA, 1990, 153 (05) :274-276
[5]  
BENHAMOU JP, 1993, GUT S2, V34
[6]  
BOTTI P, 1992, ARCH VIROL, P329
[7]  
Brind A. M., 1995, Hepatology, V22, p385A, DOI 10.1016/0270-9139(95)95261-6
[8]   HEPATITIS-C SEROTYPE AND RESPONSE TO INTERFERON THERAPY [J].
CHEMELLO, L ;
ALBERTI, A ;
ROSE, K ;
SIMMONDS, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (02) :143-143
[9]   HEPATITIS-C VIRUS-INFECTION AMONG A COHORT OF VICTORIAN INJECTING DRUG-USERS [J].
CROFTS, N ;
HOPPER, JL ;
BOWDEN, DS ;
BRESCHKIN, AM ;
MILNER, R ;
LOCARNINI, SA .
MEDICAL JOURNAL OF AUSTRALIA, 1993, 159 (04) :237-241
[10]  
DONOGHOE MC, 1991, DRUGLINK JAN, P8